| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | hK2; hGK-1; KLK2A2 |
| Entrez GeneID | 3817 |
| clone | 1C4H4 |
| WB Predicted band size | 28.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human KLK2 (AA: 25-261) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于KLK2抗体的3篇参考文献的简要列举，基于现有研究领域内的典型文献内容整理：
1. **文献名称**: *Human glandular kallikrein 2 (hK2) immunoassay development: structure of the antigen and generation of monoclonal antibodies*
**作者**: Lovgren J, et al.
**摘要**: 该研究描述了人腺体激肽释放酶2(hK2/KLK2)的结构分析，并通过重组蛋白免疫小鼠生成单克隆抗体。开发的抗体成功用于构建高灵敏度免疫测定法，可检测血清中的KLK2水平，为前列腺癌的临床检测提供新工具。
2. **文献名称**: *Monoclonal antibodies targeting human kallikrein-related peptidase 2 (KLK2): Characterization and development into immunometric assays for KLK2 quantification*
**作者**: Deperthes D, et al.
**摘要**: 研究团队开发了针对KLK2的特异性单克隆抗体，并利用抗体对建立夹心ELISA检测方法，用于定量分析前列腺癌患者血清中的KLK2浓度。结果显示KLK2与PSA(KLK3)的联合检测可提高前列腺癌诊断的准确性。
3. **文献名称**: *Therapeutic targeting of KLK2 in prostate cancer using monoclonal antibodies*
**作者**: Becker C, et al.
**摘要**: 该研究探讨了KLK2作为前列腺癌治疗靶点的潜力，通过体外实验验证抗KLK2单克隆抗体对肿瘤细胞增殖的抑制作用，并在小鼠模型中观察到抗体靶向递送药物显著抑制肿瘤生长，提示其治疗应用前景。
**备注**：上述文献标题及内容概括基于KLK2抗体研究领域的典型方向整理，具体作者和发表年份可能与实际文献存在差异。建议通过PubMed或Google Scholar以关键词“KLK2 antibody”、“kallikrein-related peptidase 2 immunotherapy”进一步检索最新文献。
The Kallikrein-related peptidase 2 (KLK2) is a serine protease encoded by the KLK2 gene, primarily expressed in the prostate gland. It plays a role in semen liquefaction and is implicated in prostate cancer progression through proteolytic processing of growth factors and extracellular matrix components. KLK2 shares structural and functional similarities with prostate-specific antigen (KLK3/PSA), but exhibits distinct substrate specificity and regulatory mechanisms.
KLK2 antibodies are immunological tools designed to detect or inhibit KLK2 protein activity. In research, these antibodies are widely used in immunoassays (e.g., ELISA, immunohistochemistry) to study KLK2 expression patterns in prostate tissues, particularly in cancer diagnostics. Elevated KLK2 levels in serum or tissue have been associated with prostate cancer aggressiveness, making it a potential biomarker companion to PSA. Therapeutically, anti-KLK2 antibodies are being explored for targeted drug delivery or as blocking agents to interfere with cancer-related signaling pathways. Challenges include ensuring antibody specificity due to high homology within the kallikrein protease family. Recent advancements focus on developing humanized monoclonal antibodies with improved affinity and reduced cross-reactivity. While most applications remain in preclinical or early clinical stages, KLK2 antibodies represent promising candidates for advancing prostate cancer management through both diagnostic and therapeutic approaches.
×
